Guardant Health (NASDAQ:GH) Director Medina Manuel Hidalgo Sells 1,700 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) Director Medina Manuel Hidalgo sold 1,700 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $164.24, for a total transaction of $279,208.00. Following the sale, the director directly owned 4,556 shares of the company’s stock, valued at approximately $748,277.44. The trade was a 27.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Medina Manuel Hidalgo also recently made the following trade(s):

• On Thursday, May 28th, Medina Manuel Hidalgo sold 1,000 shares of Guardant Health stock. The stock was sold at an average price of $130.06, for a total value of $130,060.00.
• On Wednesday, May 20th, Medina Manuel Hidalgo sold 1,250 shares of Guardant Health stock. The stock was sold at an average price of $107.09, for a total value of $133,862.50.

Guardant Health Trading Down 3.4%

NASDAQ GH traded down $5.60 during trading hours on Thursday, reaching $157.58. 1,513,030 shares of the company’s stock were exchanged, compared to its average volume of 2,317,783. The firm has a fifty day moving average of $145.75 and a 200-day moving average of $114.50. Guardant Health, Inc. has a one year low of $48.25 and a one year high of $176.58. The stock has a market cap of $21.15 billion, a PE ratio of -45.15 and a beta of 1.60.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Alyeska Investment Group L.P. bought a new stake in shares of Guardant Health in the third quarter valued at about $114,421,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Guardant Health by 33.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after purchasing an additional 1,414,441 shares during the last quarter. Norges Bank acquired a new position in Guardant Health during the fourth quarter worth $128,499,000. Summit Partners Public Asset Management LLC boosted its holdings in Guardant Health by 674.5% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 851,958 shares of the company’s stock worth $87,019,000 after purchasing an additional 741,958 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in Guardant Health by 89.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 1,205,701 shares of the company’s stock valued at $111,371,000 after buying an additional 569,766 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on GH. Barclays increased their target price on Guardant Health from $150.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. TD Cowen upped their price target on shares of Guardant Health from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Mizuho increased their price objective on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. JPMorgan Chase & Co. raised their price objective on shares of Guardant Health from $185.00 to $195.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Finally, Stifel Nicolaus boosted their target price on shares of Guardant Health from $130.00 to $180.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $183.78.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.